LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
about
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTrials with 'epigenetic' drugs: an updateEpigenetic drugs against cancer: an evolving landscape.Novel drugs for older patients with acute myeloid leukemia.Panobinostat for the treatment of acute myelogenous leukemia.
P2860
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@ast
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@en
type
label
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@ast
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@en
prefLabel
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@ast
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@en
P2093
P2860
P1433
P1476
LBH-589 (panobinostat) potenti ...... and XIAP-dependent mechanism.
@en
P2093
Roberto Rosato
Stefanie Hock
Steven Grant
P2860
P304
P356
10.1016/J.LEUKRES.2011.10.020
P50
P577
2011-11-08T00:00:00Z